(Cholecalciferol + raloxifene) is under clinical development by Addpharma and currently in Phase I for Post Menopausal Osteoporosis. According to GlobalData, Phase I drugs for Post Menopausal Osteoporosis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Cholecalciferol + raloxifene)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cholecalciferol + raloxifene) overview
Fixed dose combination of cholecalciferol and raloxifene is under development for the treatment of postmenopausal osteoporosis. It is formulated as the tablet and administered through oral route. Cholecalciferol acts by targeting calcitriol receptor and raloxifene acts by targeting estrogen receptor.
Addpharma is a specialized pharmaceutical company that develops medicinal novel drugs including complexes, release controlling agents, and absorption improving agents. Addpharma is headquartered in Yongin, South Korea.
For a complete picture of (Cholecalciferol + raloxifene)’s drug-specific PTSR and LoA scores, buy the report here.